Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alagebrium in Chronic Heart Failure
NCT00739687Phase 2Terminated
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Aug 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing Alagebrium with Placebo (2 arms). Primary endpoint: Aerobic Capacity (VO2 max) at 9 months. Started Aug 2008; status: terminated.
02
Drugs
alagebrium
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT00739687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00739687.